All News

The Sleep 2022 meeting from early June included talks on narcolepsy, the role of race in sleep disturbances, and the use of opioids in restless leg syndrome.

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.

Approximately 5.5 million people have enrolled in health care coverage through the Affordable Care Act (ACA) marketplace for 2023; the Gavi alliance is debating the end of the worldwide vaccine sharing initiative; the White House is now tracking nonfatal opioid overdoses.

Matthew Zirwas, MD, FAAD, associate professor of dermatology at Ohio University in Athens, Ohio provides updates on treatment options for AD at the 2022 SDPA Fall Conference.

This paper follows the 10-year remission mark for the first child treated with CD19-targeted CAR (chimeric antigen receptor) T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL), adding promise to the notion that the technology can provide long-term durable remissions in patients who are highly refractory to chemotherapy.

Jose P. Leone, MD, director of the program for breast cancer in men at the Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, shares why patients and providers need to pay more attention to how breast cancer impacts male patients.

Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.

A highlight of day 2 at the San Antonio Breast Cancer Symposium was the morning presentation of a pair of studies highlighting the ongoing survival benefit associated with trastuzumab deruxtecan in metastatic breast cancer.

The novel coalition was announced at the Institute for Healthcare Improvement (IHI) Forum, which took place December 4-7 in Orlando, Florida.

Dawn L. Hershman, MD, an oncologist from Columbia University, shared insight into the current challenge of ensuring drug adherence within clinical trials and how this adherence can impact the quality of care for patients in real-world settings.

Safety and efficacy were the most important factors for patients with hemophilia learning about gene therapies, although more research is needed to see how collaboration between providers and patients contributes to the best outcomes.

Frequency of orthostatic hypotension among Ethiopian patients with Parkinson disease (PD) was shown to be higher than that among healthy controls, with a higher proportion of constipation, urinary urgency, and nocturia symptoms reported in those with PD.

The end or relaxation of COVID-19 restrictions was associated with increased risk of severe asthma attacks.

Sexually transmitted infections (STIs) are on the rise in the United States and have significant health and economic impacts, but pharmacists can help combat the spread as they work with affected patients.

No difference was shown regarding pregnancy and childbirth outcomes among patients with polycystic ovary syndrome (PCOS) who receive oocytes from women with or without PCOS.

Patients with type 2 diabetes can determine their risk of chronic kidney disease (CKD) by using a risk prediction model.

Irene M. Kang, MD, from City of Hope, shared some of the results from her analysis of cognitive impairment in women with breast cancer who participated in the RxPonder study, which assessed which patients would benefit most from chemotherapy.

CMS proposed a rule to streamline the prior authorization process and expand health information access; a scathing report urged the FDA to consider restructuring and potentially dividing the agency; the Institute for Healthcare Improvement (IHI) and American Medical Association (AMA) are coleading the Rise to Health Coalition.

Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Speaking with patients diagnosed with chronic kidney disease (CKD) about the burdens associated with care could help improve understanding of the disease and their communication with health care professionals.

Costs are an adverse effect of treatment just like any other adverse effect, with slightly more patients worried about the financial impact of their cancer diagnosis than they are about actually dying from their disease, noted Fumiko Chino, MD, of Memorial Sloan Kettering (MSK) Cancer Center.

Patients with diabetes may benefit from continuous glucose monitoring (CGM) as a standard of care in the primary care setting, according to a recent study that assessed clinicians’ attitudes toward prescribing these tools.

Can a patient with metastatic cancer on immune checkpoint inhibitor (ICI) therapy use acetaminophen for pain? What about medical marijuana? And does the gut microbiome play a role? With more than a decade of real-world experience with ICIs, pharmacists learned about the potential role of these and other factors during a session at the 2022 American Society of Health-System Pharmacy Midyear Clinical Meeting & Exhibition.

Meibomian gland dysfunction, an etiological factor of dry eye disease, showed promising results in response to treatment with intense pulsed light.

A cross-sectional study showed that patients experiencing homelessness were at more than 2-fold greater age-adjusted mortality risk due to COVID-19 compared with the general population, with these increased risks observed across race/ethnicity and sex status.

Increasing rates of marijuana consumption highlights a need for research on the effects of smoking marijuana on the lungs.

In a recent study, it was found that individuals with public health insurance had worse health competence beliefs, reducing transition goals, expectations, and beliefs.

Patients with diabetes who reported use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or metformin prior to COVID-19 infection were associated with lower COVID-19–related adverse outcomes during hospitalization.